• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童代谢相关脂肪性肝病——从微观到整体

Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.

作者信息

Mărginean Cristina Oana, Meliț Lorena Elena, Săsăran Maria Oana

机构信息

Department of Pediatrics I, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, Gheorghe Marinescu Street No 38, 540136 Târgu Mureș, Romania.

Department of Pediatrics III, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, Gheorghe Marinescu Street No 38, 540136 Târgu Mureș, Romania.

出版信息

Biomedicines. 2021 Dec 9;9(12):1866. doi: 10.3390/biomedicines9121866.

DOI:10.3390/biomedicines9121866
PMID:34944682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8698557/
Abstract

Non-alcoholic fatty liver disease has become the most common chronic liver disease in children due to the alarmingly increasing incidence of pediatric obesity. It is well-documented that MAFLD prevalence is directly related to an incremental increase in BMI. The multiple hits theory was designed for providing insights regarding the pathogenesis of steatohepatitis and fibrosis in MAFLD. Recent evidence suggested that the microbiome is a crucial contributor in the pathogenesis of MAFLD. Aside from obesity, the most common risk factors for pediatric MAFLD include male gender, low-birth weight, family history of obesity, MAFLD, insulin resistance, type 2 diabetes mellitus, obstructive sleep apnea, and polycystic ovarium syndrome. Usually, pediatric patients with MAFLD have nonspecific symptoms consisting of fatigue, malaise, or diffuse abdominal pain. A wide spectrum of biomarkers was proposed for the diagnosis of MAFLD and NASH, as well as for quantifying the degree of fibrosis, but liver biopsy remains the key diagnostic and staging tool. Nevertheless, elastography-based methods present promising results in this age group as potential non-invasive replacers for liver biopsy. Despite the lack of current guidelines regarding MAFLD treatment in children, lifestyle intervention was proven to be crucial in the management of these patients.

摘要

由于儿童肥胖发病率惊人地上升,非酒精性脂肪性肝病已成为儿童中最常见的慢性肝病。有充分的文献记载,MAFLD患病率与BMI的逐渐增加直接相关。多重打击理论旨在为MAFLD中脂肪性肝炎和纤维化的发病机制提供见解。最近的证据表明,微生物群是MAFLD发病机制中的一个关键因素。除肥胖外,儿童MAFLD最常见的危险因素包括男性、低出生体重、肥胖家族史、MAFLD、胰岛素抵抗、2型糖尿病、阻塞性睡眠呼吸暂停和多囊卵巢综合征。通常,患有MAFLD的儿科患者有非特异性症状,包括疲劳、不适或弥漫性腹痛。人们提出了各种各样的生物标志物用于MAFLD和NASH的诊断,以及量化纤维化程度,但肝活检仍然是关键的诊断和分期工具。然而,基于弹性成像的方法在这个年龄组中显示出有希望的结果,作为肝活检的潜在非侵入性替代方法。尽管目前缺乏关于儿童MAFLD治疗的指南,但生活方式干预已被证明对这些患者的管理至关重要。

相似文献

1
Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.儿童代谢相关脂肪性肝病——从微观到整体
Biomedicines. 2021 Dec 9;9(12):1866. doi: 10.3390/biomedicines9121866.
2
Lack of awareness and ethnic polarity is a major cause of metabolic associated fatty liver disease in high-risk diabetes population in South London.缺乏认知和种族两极分化是伦敦南部高危糖尿病患者代谢相关脂肪性肝病的主要原因。
Ther Adv Chronic Dis. 2024 Jul 30;15:20406223241264539. doi: 10.1177/20406223241264539. eCollection 2024.
3
MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.用于肝脂肪变性、非酒精性脂肪性肝炎和肝纤维化诊断的MAFLD/NAFLD无创评分系统
Front Med (Lausanne). 2022 Jan 13;8:774079. doi: 10.3389/fmed.2021.774079. eCollection 2021.
4
Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem.儿童代谢性脂肪肝病:一个日益严重的公共卫生问题。
Biomedicines. 2021 Dec 14;9(12):1915. doi: 10.3390/biomedicines9121915.
5
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.肥胖的病理生理分子机制:MAFLD 和 NASH 与心血管疾病的联系。
Int J Mol Sci. 2021 Oct 27;22(21):11629. doi: 10.3390/ijms222111629.
6
Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?代谢相关性脂肪性肝病病理生理学的当前观点:巨噬细胞是否是治疗的可行靶点?
Expert Rev Gastroenterol Hepatol. 2021 Jan;15(1):51-64. doi: 10.1080/17474124.2020.1817740. Epub 2020 Sep 17.
7
A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health.代谢相关脂肪性肝病(MAFLD)在全球范围内及墨西哥的儿童和青少年中流行率不断上升的研究综述及其对公共卫生的影响。
Med Sci Monit. 2021 Aug 30;27:e934134. doi: 10.12659/MSM.934134.
8
Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease.溶酶体酸性脂肪酶(LAL)活性水平低会增加经活检证实患有代谢相关脂肪性肝病的成年患者的坏死性炎症。
Clin Res Hepatol Gastroenterol. 2021 Nov;45(6):101638. doi: 10.1016/j.clinre.2021.101638. Epub 2021 Mar 1.
9
Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children.儿童代谢相关脂肪性肝病(MAFLD)的研究进展。
J Pediatr Gastroenterol Nutr. 2023 Nov 1;77(5):583-591. doi: 10.1097/MPG.0000000000003919. Epub 2023 Aug 18.
10
Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.从非酒精性脂肪性肝病到代谢相关性脂肪性肝病的转变中的未决问题:Plinio 研究的经验。
Int J Environ Res Public Health. 2021 Aug 26;18(17):8993. doi: 10.3390/ijerph18178993.

引用本文的文献

1
Potential alternative and novel biomarkers for paediatric MAFLD: exploratory evidence from a Chinese cohort.儿童代谢功能障碍相关脂肪性肝病的潜在替代生物标志物和新型生物标志物:来自中国队列的探索性证据。
BMC Gastroenterol. 2025 Jan 22;25(1):28. doi: 10.1186/s12876-025-03619-2.
2
Childhood obesity in South Asian population.南亚人群中的儿童肥胖问题。
Obes Pillars. 2024 Oct 30;12:100148. doi: 10.1016/j.obpill.2024.100148. eCollection 2024 Dec.
3
Thrombospondin-2 as a potential noninvasive biomarker of hepatocyte injury but not liver fibrosis in children with MAFLD: A preliminary study.血小板反应蛋白-2作为非酒精性脂肪性肝病合并代谢功能障碍儿童肝细胞损伤而非肝纤维化的潜在无创生物标志物:一项初步研究。
Clin Exp Hepatol. 2023 Dec;9(4):368-374. doi: 10.5114/ceh.2023.133108. Epub 2023 Nov 22.
4
The effects of weight loss interventions on children and adolescents with non-alcoholic fatty liver disease: A systematic review and meta-analysis.减肥干预措施对非酒精性脂肪性肝病儿童及青少年的影响:一项系统评价与荟萃分析。
Obes Sci Pract. 2024 Apr 26;10(3):e758. doi: 10.1002/osp4.758. eCollection 2024 Jun.
5
Neutrophils: tissue and circulating signatures of pediatric non-alcoholic fatty liver disease.中性粒细胞:儿童非酒精性脂肪性肝病的组织和循环特征
Front Cell Dev Biol. 2024 Jan 4;11:1336033. doi: 10.3389/fcell.2023.1336033. eCollection 2023.
6
Evaluation of the clinical value of shear wave elastography for early detection and diagnosis of diabetic peripheral neuropathy: a controlled preliminary prospective clinical study.剪切波弹性成像在早期发现和诊断糖尿病周围神经病变中的临床价值评估:一项对照性初步前瞻性临床研究。
BMC Musculoskelet Disord. 2022 Dec 22;23(1):1120. doi: 10.1186/s12891-022-06085-z.
7
The Yin-Yang Concept of Pediatric Obesity and Gut Microbiota.小儿肥胖与肠道微生物群的阴阳概念
Biomedicines. 2022 Mar 10;10(3):645. doi: 10.3390/biomedicines10030645.

本文引用的文献

1
The assessment of liver fibrosis in children with obesity on two methods: transient and two dimensional shear wave elastography.两种方法评估肥胖儿童的肝纤维化:瞬时弹性成像和二维剪切波弹性成像。
Sci Rep. 2019 Dec 24;9(1):19800. doi: 10.1038/s41598-019-56358-2.
2
The adipokines and inflammatory status in the era of pediatric obesity.在小儿肥胖症时代的脂肪因子和炎症状态。
Cytokine. 2020 Feb;126:154925. doi: 10.1016/j.cyto.2019.154925. Epub 2019 Nov 20.
3
NAFLD in children: new genes, new diagnostic modalities and new drugs.儿童非酒精性脂肪性肝病:新基因、新诊断方法和新药物。
Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):517-530. doi: 10.1038/s41575-019-0169-z. Epub 2019 Jul 5.
4
Early Inflammatory Status Related to Pediatric Obesity.与儿童肥胖相关的早期炎症状态
Front Pediatr. 2019 Jun 18;7:241. doi: 10.3389/fped.2019.00241. eCollection 2019.
5
The Discovery and Development of Liraglutide and Semaglutide.利拉鲁肽和司美格鲁肽的发现与研发
Front Endocrinol (Lausanne). 2019 Apr 12;10:155. doi: 10.3389/fendo.2019.00155. eCollection 2019.
6
Pediatric NAFLD: an overview and recent developments in diagnostics and treatment.儿科非酒精性脂肪性肝病:概述及诊断和治疗的最新进展。
Expert Rev Gastroenterol Hepatol. 2019 May;13(5):447-461. doi: 10.1080/17474124.2019.1595589. Epub 2019 Apr 4.
7
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE and LDLr Mice by a Mechanism That Includes Inflammatory Pathways.胰高血糖素样肽-1类似物利拉鲁肽和司美格鲁肽通过包括炎症途径在内的机制减轻载脂蛋白E和低密度脂蛋白受体基因敲除小鼠的动脉粥样硬化。
JACC Basic Transl Sci. 2018 Nov 21;3(6):844-857. doi: 10.1016/j.jacbts.2018.09.004. eCollection 2018 Dec.
8
Role of vitamin E in nonalcoholic fatty liver disease.维生素 E 在非酒精性脂肪性肝病中的作用。
IUBMB Life. 2019 Apr;71(4):516-522. doi: 10.1002/iub.1991. Epub 2018 Dec 27.
9
A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease.氯沙坦治疗小儿非酒精性脂肪性肝病的随机、对照、交叉试验性研究。
Pilot Feasibility Stud. 2018 Jun 5;4:109. doi: 10.1186/s40814-018-0306-4. eCollection 2018.
10
Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease.蛋白磷酸酶1调节亚基3B基因变异可预防非酒精性脂肪性肝病高危个体的肝脏脂肪堆积和纤维化。
Hepatol Commun. 2018 Apr 25;2(6):666-675. doi: 10.1002/hep4.1192. eCollection 2018 Jun.